Ultragenyx announces positive interim data from phase 2 study of UX007
Ultragenyx announced positive interim data on the acute effects of the investigational treatment UX007 (triheptanoin) at the end of the initial 24-week treatment period of the Phase 2 study in long-chain fatty acid oxidation disorder patients. October 13, 2015